Antibody-Drug Conjugates – Special Topics – Special Topics: Antibody-Drug Conjugates

Antibody-drug conjugates have proven to be a versatile and effective tool in treating a wide range of tumor types, establishing the drug class as a valuable weapon against cancer. The approval of agents targeting various extracellular antigens associated with tumorigenesis continues to transform the treatment paradigm for a plethora of oncology indications. The late-phase pipeline is particularly active and promising. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates in select oncology indications and analyzes key market trends and dynamics.


  • What is the current landscape for approved antibody-drug conjugates? What are their approval timelines?
  • What is the market positioning of emerging antibody-drug conjugates?
  • How will the indication-specific market trends and dynamics evolve?
  • What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, and geography? How will the market evolve over the 2022-2032 forecast period?


United States, EU5, Japan.


Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.


10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.


Select approved therapies (e.g., Enhertu, Kadcyla, Trodelvy, Polivy) and select emerging therapies expected to gain approval.


Agents in Phase 3 development.


Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.